Coherus Biosciences (CHRS) Stock Buy Rating Reaffirmed at Credit Suisse; The PT is $25; Integrated Device Technology (IDTI) Sellers Decreased By 1.86% Their Shorts

Integrated Device Technology, Inc. (NASDAQ:IDTI) Logo

Integrated Device Technology Inc (NASDAQ:IDTI) had a decrease of 1.86% in short interest. IDTI’s SI was 13.65M shares in March as released by FINRA. Its down 1.86% from 13.91 million shares previously. With 2.65M avg volume, 5 days are for Integrated Device Technology Inc (NASDAQ:IDTI)’s short sellers to cover IDTI’s short positions. The SI to Integrated Device Technology Inc’s float is 10.7%. The stock decreased 0.04% or $0.02 during the last trading session, reaching $48.33. About 71,910 shares traded. Integrated Device Technology, Inc. (NASDAQ:IDTI) has risen 60.97% since March 11, 2018 and is uptrending. It has outperformed by 56.60% the S&P500. Some Historical IDTI News: 10/04/2018 – Integrated Device Closes Above 50-Day Moving Average; 30/04/2018 – INTEGRATED DEVICE 4Q ADJ EPS 46C, EST. 44C; 01/05/2018 – Integrated Device Volume Jumps More Than Six Times Average; 26/04/2018 – IDT Introduces Synchronous Ethernet Solution for 4G/5G Mobile Networks Using Marvell PHYs; 07/05/2018 – Integrated Device Presenting at JPMorgan Conference May 15; 30/04/2018 – INTEGRATED DEVICE 4Q REV. $224.6M, EST. $222.2M; 30/04/2018 – Integrated Device Tech 4Q Rev $224.6M; 23/03/2018 – Integrated Device Closes Below 50-Day Moving Average; 04/04/2018 – Xiaomi Selects IDT® Wireless Charging Chipset for MI MIX 2S Smartphone and Wireless Charging Pad; 16/04/2018 – Samsung’s Galaxy S9 and Galaxy S9+ Smartphones are Powered by IDT® Wireless Charging Chipsets

They currently have a $25 target on Coherus Biosciences (NASDAQ:CHRS). Credit Suisse’s target would suggest a potential upside of 74.22% from the company’s last stock close. This was revealed to investors in analysts note on 7 March.

Integrated Device Technology, Inc. designs, develops, makes, and markets a range of semiconductor solutions for the communications, computing, consumer, automotive, industrial, and Internet-of-things end-markets. The company has market cap of $6.25 billion. It operates in two divisions, Communications; and Computing, Consumer, and Industrial. It has a 59.37 P/E ratio. The Communications segment offers clocks and timing solutions; flow-control management devices comprising Serial RapidIO switching solutions; multi-port products; telecommunications products; static random access memory products; first in and first out memories; digital logic products; radio frequency products; and frequency control solutions.

Since September 14, 2018, it had 0 insider buys, and 1 sale for $1.57 million activity. Shares for $1.57 million were sold by Chittipeddi Sailesh.

Investors sentiment decreased to 0.84 in Q4 2018. Its down 0.01, from 0.85 in 2018Q3. It worsened, as 36 investors sold Integrated Device Technology, Inc. shares while 105 reduced holdings. 53 funds opened positions while 65 raised stakes. 111.18 million shares or 1.29% less from 112.64 million shares in 2018Q3 were reported. Verition Fund Limited Liability holds 0.02% or 5,014 shares in its portfolio. First Manhattan Co owns 12,175 shares or 0% of their US portfolio. First Citizens Commercial Bank & Tru Co accumulated 5,871 shares or 0.03% of the stock. Myriad Asset Mngmt Ltd accumulated 451,547 shares. Moreover, Texas Permanent School Fund has 0.07% invested in Integrated Device Technology, Inc. (NASDAQ:IDTI) for 84,439 shares. Rothschild & Com Asset Mngmt Us, a New York-based fund reported 84,090 shares. Congress Asset Management Com Ma reported 52,767 shares. First Hawaiian Natl Bank has invested 0% in Integrated Device Technology, Inc. (NASDAQ:IDTI). Natixis Advsr Limited Partnership holds 0.06% or 125,469 shares in its portfolio. Carlson Cap Limited Partnership holds 0.82% or 1.09 million shares in its portfolio. Credit Suisse Ag has 2.20M shares. First Interstate Natl Bank invested in 0.04% or 3,155 shares. Fil invested 0.09% in Integrated Device Technology, Inc. (NASDAQ:IDTI). The New York-based Sg Americas Securities Limited Co has invested 0.01% in Integrated Device Technology, Inc. (NASDAQ:IDTI). Trigran Invests reported 165,350 shares.

More notable recent Integrated Device Technology, Inc. (NASDAQ:IDTI) news were published by: Nasdaq.com which released: “Notable ETF Outflow Detected – IWM, FIVE, ETSY, IDTI – Nasdaq” on February 27, 2019, also Prnewswire.com with their article: “IDT Announces 64G Linear Modulator Driver Series for Coherent Applications – PRNewswire” published on March 06, 2019, Prnewswire.com published: “IDT Releases Low Power, Multi-rate PAM4 Linear TIA for 200G/400G Datacom Interconnects and 5G Wireless Applications – PRNewswire” on March 05, 2019. More interesting news about Integrated Device Technology, Inc. (NASDAQ:IDTI) were released by: Prnewswire.com and their article: “IDT Leads Growing AAS Market with Innovative Infrastructure Products for 4G and 5G Network Rollouts – PRNewswire” published on February 28, 2019 as well as Prnewswire.com‘s news article titled: “IDT and viRaTec Expand Cooperation for Development of 6LoWPAN Wireless Solutions in Smart Irrigation Systems – PRNewswire” with publication date: February 19, 2019.

Investors sentiment increased to 1.29 in Q4 2018. Its up 0.18, from 1.11 in 2018Q3. It improved, as 17 investors sold Coherus BioSciences, Inc. shares while 25 reduced holdings. 22 funds opened positions while 32 raised stakes. 59.12 million shares or 0.82% less from 59.61 million shares in 2018Q3 were reported. Royal Savings Bank Of Canada holds 0% or 95,998 shares in its portfolio. Barclays Public Ltd invested in 2,596 shares or 0% of the stock. State Street Corp invested in 2.64M shares or 0% of the stock. Pura Vida Invests Lc has 1.19% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS). Huntington Financial Bank stated it has 1 shares or 0% of all its holdings. Platinum Invest Mgmt Limited owns 215,084 shares. Tekla Capital Mngmt Ltd Liability Corporation holds 315,162 shares. Bancshares Of New York Mellon Corp owns 222,542 shares. Pier Cap Ltd Co reported 607,596 shares stake. Secor Capital Advsrs Limited Partnership holds 0.03% or 21,703 shares. Sectoral Asset Inc has invested 0.03% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS). 11,450 are owned by Hightower Advisors Limited Liability Corporation. Manufacturers Life Ins The holds 0% or 32,333 shares. Mirae Asset Investments Limited has 290,687 shares for 0.02% of their portfolio. Royal London Asset Mngmt has invested 0.01% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Analysts await Coherus BioSciences, Inc. (NASDAQ:CHRS) to report earnings on May, 9. They expect $-0.40 EPS, up 45.95% or $0.34 from last year’s $-0.74 per share. After $-0.92 actual EPS reported by Coherus BioSciences, Inc. for the previous quarter, Wall Street now forecasts -56.52% EPS growth.

Among 2 analysts covering Coherus Biosciences (NASDAQ:CHRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherus Biosciences has $25 highest and $25 lowest target. $25’s average target is 74.22% above currents $14.35 stock price. Coherus Biosciences had 2 analyst reports since March 1, 2019 according to SRatingsIntel. The stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) has “Buy” rating given on Friday, March 1 by Maxim Group. Credit Suisse maintained it with “Buy” rating and $25 target in Thursday, March 7 report.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $993.88 million. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Globenewswire.com which released: “Coherus BioSciences Announces New Employment Inducement Grants – GlobeNewswire” on February 22, 2019, also Nasdaq.com with their article: “Here’s Why Coherus BioSciences Rose 48.7% in January – Nasdaq” published on February 11, 2019, Nasdaq.com published: “Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results – Nasdaq” on February 28, 2019. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: Globenewswire.com and their article: “New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe’s Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” published on March 05, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs – Yahoo Finance” with publication date: February 22, 2019.

Integrated Device Technology, Inc. (NASDAQ:IDTI) Institutional Positions Chart

"

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.